World Library  
Flag as Inappropriate
Email this Article

ViiV Healthcare

Article Id: WHEBN0029174826
Reproduction Date:

Title: ViiV Healthcare  
Author: World Heritage Encyclopedia
Language: English
Subject: GlaxoSmithKline, Allen & Hanburys, Pharmaceutical industry in the United Kingdom, Side Effects (Bass book), Beecham Group
Collection:
Publisher: World Heritage Encyclopedia
Publication
Date:
 

ViiV Healthcare

ViiV Healthcare
Type Joint venture
Industry Healthcare
Founded November 2009 (2009-11)
Headquarters Brentford, Greater London, UK
Area served Global
Key people Dominique Limet, (CEO)
Products Pharmaceuticals
Parent
Website Official website

ViiV Healthcare is a pharmaceutical company specialising in the development of therapies for HIV that was created as a joint venture by Pfizer and GlaxoSmithKline in November 2009 with both companies transferring their HIV assets to the new company.[1] In 2012 Shionogi joined the company. 76.5% of the company is now owned by GlaxoSmithKline, 13.5% by Pfizer and 10% by Shionogi.[2] This ownership structure may change depending upon the achievement of certain milestones.[1]

ViiV Healthcare's products have a market share of approximately 19 percent[3] of the global HIV market, which makes it the second largest health care company, following after Gilead Sciences, that is working on the treatment of HIV.[4]

ViiV Healthcare's headquarters are in Brentford in the United Kingdom and it has sites in a number of other countries including; the United States, Australia, Belgium, Canada, France, Germany, Italy, Japan, Mexico, the Netherlands, Portugal, Puerto Rico, Russia, Spain and Switzerland.[5]

Products

The company currently markets 12 products:[6][7]

Treatment access programs

ViiV Healthcare has stated that it will continue the not-for-profit pricing schemes that Pfizer and GlaxoSmithKline had been involved in prior to the setting up of the company. This program covers all low and middle income countries, as well as all of Sub-Saharan Africa.[8]

The company has also granted voluntary licenses to 14 generics companies to enable the low cost manufacture and sale of generic versions of the company's products in specific countries and/or regions.[9][10]

Criticisms

The foundation of ViiV Healthcare has been criticised by Treatment Action Group which had suspicions about the motives behind Pfizer and GlaxoSmithKline's desire to form the new company. The group's concerns centred on the possibility that the two pharmaceutical companies were using ViiV Healthcare as a way to get out of a field of research that has not been particularly commercially successful.[1]

See also

References

  1. ^ a b c Jacks, Andrew "GSK and Pfizer to merge HIV portfolios Financial Times. 16 April 2010
  2. ^ "Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio". viivhealthcare.com. Retrieved 2014-03-07. 
  3. ^ "ViiV company website – about us" Accessed 13 October 2010
  4. ^ Jacks, Andrew "ViiV vows joint venture will help fight HIV" Financial Times. 3 November 2009
  5. ^ "ViiV company website – about us" Accessed 13 October 2010
  6. ^ "ViiV company website – products" Accessed 13 October 2010
  7. ^ McNeil, Donald "AIDS Divisions of 2 Large Drug Makers Form Company to Focus on the Disease" New York Times. 9 November 2009
  8. ^ "ViiV company website – access to medicines" Accessed 12 January 2014
  9. ^ "ViiV company website – access to medicines" Accessed 12 January 2014
  10. ^ Reuters "Glaxo, Pfizer JV opens HIV pipeline to generic companies" Africa – the good news, 19 July 2010


This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.